Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Lymphoma 2Breast Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 41Nivolumab 18atezolizumab 8Specimen Handling 7Docetaxel 7durvalumab 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Ipilimumab 6Cyclophosphamide 6Carboplatin 6fludarabine 4avelumab 4Oxaliplatin 4Leucovorin 4Early Intervention, Educational 4Counseling 4Biopsy 4temsirolimus 3spartalizumab 3pazopanib 3olaparib 3lenvatinib 3cabozantinib 3aldesleukin 3Trastuzumab 3Taxes 3Sirolimus 3Psychiatric Rehabilitation 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × valspodar × Gynecologic × Clear all
NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
52 enrolled
BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡